BOPA 2017 | The changing landscape of NSCLC diagnosis, monitoring and treatment

Yvonne Summers

Knowledge about the different subtypes of and mutations within NSCLC has increased dramatically in the past 10 years. Here, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK discusses changes in the diagnosis and treatment of NSCLC as a result of this increased understanding. Key areas covered include resistance to EGFR TKIs, such as that caused by the T790M mutation, repeat biopsies and whether ctDNA could be used as an alternative or complementary method of mutation identification. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

Share this video